CoChat

Molecular landscape of ERBB2 alterations in 3000 advanced NSCLC patients

Open access
Hong, Lingzhi, Patel, Sonia, Drusbosky, Leylah M., Xiong, Yuanyuan, Chen, Rongrong, Geng, Ruixuan, Heeke, Simon, Nilsson, Monique, Wu, Jia, Heymach, John V., Wang, Yingyi, Zhang, Jianjun, Le, Xiuning · 2024 · npj Precision Oncology
Cited by 55

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

ERBB2 (HER2) represents a newly recognized actionable oncogenic driver in non-small cell lung cancer (NSCLC), with approved targeted therapy available. Understanding the landscape of ERBB2 alterations and co-occurring mutations is essential for guiding treatment decisions. We conducted an analysis involving 3000 NSCLC patients with all types of ERBB2 alterations, drawn from two extensive retrospective cohorts: 1281 from Geneplus (Chinese) and 1719 from Guardant360 (the United States, US). The incidence of all types of ERBB2 alterations was found to be 5.6% in the Chinese group and 5.2% in the US group. In both cohorts, among oncogenic alterations of ERBB2, exon 20 insertion Y772_A775dupYVMA was the most frequent alteration (58% vs 41.6% in the Chinese vs the US), followed by G776delinsVC/LC/VV/IC (10.7% vs 9.7%), and S310X (10.5% vs 15.4%). EGFR ex20 insertions were identified in the A767-V774 region, whereas ERBB2 ex20 insertions were observed in the Y772-P780 region. Notably, EGFR ex20 insertions exhibited greater insertion diversity. Clinical characteristics of EGFR and ERBB2 ex20 NSCLC were similar, characterized by low tumor mutation burden (TMB), a predominant never-smoker population, and a majority of lung adenocarcinoma cases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41698-024-00720-9

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 55

Metadata

Authors
Hong, L., Patel, S., Drusbosky, L. M., Xiong, Y., Chen, R., Geng, R., Heeke, S., Nilsson, M., Wu, J., Heymach, J. V., Wang, Y., Zhang, J., & Le, X.
Venue
npj Precision Oncology
Published
2024-10-01
Volume
8
Issue
1
Pages
217-217
ISSN
2397-768X (ISSN-L)
OpenAlex
W4403024613
Cited by
55
References
14
FWCI
14.03
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular landscape of ERBB2 alterations in 3000 advanced NSCLC patients. https://app.cochat.ai/papers/10.1038/s41698-024-00720-9
The paper
Hong, L., Patel, S., Drusbosky, L. M., Xiong, Y., Chen, R., Geng, R., Heeke, S., Nilsson, M., Wu, J., Heymach, J. V., Wang, Y., Zhang, J., & Le, X. (2024). Molecular landscape of ERBB2 alterations in 3000 advanced NSCLC patients. npj Precision Oncology. https://doi.org/10.1038/s41698-024-00720-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.